Literature DB >> 9884428

Interleukin-6 localization and the prognosis of IgA nephropathy.

Y Taniguchi1, N Yorioka, J Kumagai, M Katsutani, M Kuratsune, D Amimoto, M Yamakido.   

Abstract

Various cytokines and growth factors may be involved in IgA nephropathy. To clarify whether interleukin-6 was a prognostic factor for this disease, we investigated interleukin-6 positivity of renal biopsy specimens and its relationship with the prognosis. The subjects were 90 patients with IgA nephropathy (42 males and 48 females with a median age of 32.7 +/- 13.8 years). Renal biopsy specimens were stained for interleukin-6 using an enzyme-antibody method. Fifty-two of 90 patients showed glomerular positivity for interleukin-6. Among the patients positive for interleukin-6, 24-hour urinary protein excretion and serum creatinine levels were significantly higher at the time of biopsy than in the patients without interleukin-6 positivity, while creatinine clearance was significantly lower. In the interleukin-6-positive patients without steroid therapy, serum creatinine increased significantly after 1 year (Deltas-Cr; 1.04 +/- 0.45 mg/dl) and creatinine clearance decreased significantly (DeltaCcr; -11.7 +/- 3.2 ml/min) compared to the interleukin-6-negative patients without steroid therapy. Steroid therapy improved 24-hour urinary protein excretion, serum creatinine, and creatinine clearance in the interleukin-6-positive patients, while these parameters worsened without steroid therapy. On the other hand, the IL-6-negative patients showed no differences of clinical parameters irrespective of the presence or absence of steroid therapy. In conclusion, glomerular interleukin-6 positivity may be a prognostic factor and an indicator of the need for steroid therapy in IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9884428     DOI: 10.1159/000045254

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  7 in total

1.  Urinary levels of interleukin-8 (IL-8) and disease activity in patients with IgA nephropathy.

Authors:  F Huang; S Horikoshi; A Kurusu; T Shibata; S Suzuki; K Funabiki; I Shirato; Y Tomino
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

2.  TLR7 in B cells promotes renal inflammation and Gd-IgA1 synthesis in IgA nephropathy.

Authors:  Nuoyan Zheng; Kaifeng Xie; Hongjian Ye; Yu Dong; Bing Wang; Ning Luo; Jinjin Fan; Jiaqing Tan; Wei Chen; Xueqing Yu
Journal:  JCI Insight       Date:  2020-07-23

3.  Interactions among glomerulus infiltrating macrophages and intrinsic cells via cytokines in chronic lupus glomerulonephritis.

Authors:  Sun-Sang J Sung; Shu Man Fu
Journal:  J Autoimmun       Date:  2019-09-05       Impact factor: 7.094

4.  IgA nephropathy in adult-onset Still's disease after tocilizumab treatment: a case report.

Authors:  Ji-Hyoun Kang
Journal:  Int Urol Nephrol       Date:  2021-07-16       Impact factor: 2.370

5.  Synergistic effect of mesangial cell-induced CXCL1 and TGF-β1 in promoting podocyte loss in IgA nephropathy.

Authors:  Li Zhu; Qingxian Zhang; Sufang Shi; Lijun Liu; Jicheng Lv; Hong Zhang
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

6.  Plasma ST6GAL1 regulates IgG sialylation to control IgA nephropathy progression.

Authors:  Youxia Liu; Huyan Yu; Sijing Wu; Xia Yang; Congcong Cao; Fanghao Wang; Junya Jia; Tiekun Yan
Journal:  Ther Adv Chronic Dis       Date:  2021-10-11       Impact factor: 5.091

Review 7.  Biological Role, Mechanism of Action and the Importance of Interleukins in Kidney Diseases.

Authors:  Paulina Mertowska; Sebastian Mertowski; Iwona Smarz-Widelska; Ewelina Grywalska
Journal:  Int J Mol Sci       Date:  2022-01-07       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.